Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy
- 7 January 2013
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Hepatology
- Vol. 57 (1), 399-408
- https://doi.org/10.1002/hep.25937
Abstract
Chronic hepatitis B (CHB) infection is the major cause of hepatocellular carcinoma (HCC). Primary prevention of hepatitis B infection by vaccination is effective in reducing the incidence of HCC. In persons with CHB infection, the two accepted treatment modalities are interferon alpha (IFN‐α) given subcutaneously for a limited period and nucleoside/nucleotide analogs given orally on a long‐term basis. These treatments are effective in suppressing viral activity and improving disease markers in short‐term studies. The long‐term effect on the development of liver cancers with these two forms of treatment appears to be different. However, there are no studies directly comparing IFN‐α and nucleoside/nucleotide analogs. Comparisons across studies are inevitably limited by differences in the baseline characteristics of the study cohorts. Long‐term follow‐up studies of IFN‐α therapy show inconsistent results. The beneficial effect in reducing the development of liver cancer is observed mainly in treatment responders who have preexisting cirrhosis of the liver. The long‐term studies of lamivudine (and adefovir) show a consistent reduction in the development of liver cancers in patients with, and without, cirrhosis. This beneficial effect is blunted by the development of resistance. The effects of the newer nucleoside/nucleotide analogs, with higher potency and minimal risk of resistance development, are, as yet, unknown. (HEPATOLOGY 2013)This publication has 32 references indexed in Scilit:
- Genome-Wide Association Study of Hepatocellular Carcinoma in Southern Chinese Patients with Chronic Hepatitis B Virus InfectionPLOS ONE, 2011
- Long-term effect of interferon treatment on the progression of chronic hepatitis B: Bayesian meta-analysis and meta-regressionHepatology Research, 2011
- Long-Term Nucleos(t)ide Analogues Therapy for Adults With Chronic Hepatitis B reduces the Risk of Long-Term Complications: a meta-analysisVirology Journal, 2011
- Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort studyGut, 2011
- Association of Hepatitis B Virus Pre-S Deletions with the Development of Hepatocellular Carcinoma in Chronic Hepatitis BThe Journal of Infectious Diseases, 2011
- Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: A systematic reviewJournal of Hepatology, 2010
- Meta-analysis: the effect of interferon on development of hepatocellular carcinoma in patients with chronic hepatitis B virus infectionThe Esophagus, 2009
- Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis BHepatology, 2004
- Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approachJournal of Hepatology, 2001
- The long-term outcome of interferon-α treated and untreated patients with HBeAg-negative chronic hepatitis BJournal of Hepatology, 2001